ArticleJAAD international2026
Patient preferences in the benefit-risk assessment of atopic dermatitis treatments in China: A nationwide survey.
Article in JAAD international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Understanding patient preferences is critical for patient-focused drug development, especially in chronic conditions like atopic dermatitis, where treatment benefit-risk profiles vary widely. Objective: To evaluate treatment priorities, risk tolerance, and benefit-risk acceptance among Chinese patients with atopic dermatitis. Methods: A nationwide, cross-sectional online survey was conducted between February and July 2023. Patients with physician-diagnosed atopic dermatitis or their caregivers were recruited via major dermatology hospitals and patient communities. The survey evaluated treatment goals, unacceptable adverse events, and willingness to accept risks under scenarios of near-complete versus partial recovery. Results: Of 2120 respondents, 1948 valid responses were analyzed. Top treatment goals were reducing flare-ups (84%), preventing complications (61%), and relieving itch and pain (52%). Most unacceptable adverse events were serious infections (67%) and malignancies (65%). Patients showed increased risk tolerance when treatments promised near-complete recovery (15% fully accepted <0.1% risk of severe reactions) versus partial improvement (10%). Risk tolerance was lower among patients under 18 years and those with mild-to-moderate disease. Limitations: Self-reported data and online recruitment may limit generalizability. Conclusion: Chinese patients are more willing to accept treatment risks when greater benefits are expected. Preferences vary by age and severity, supporting more personalized treatment discussions and decisions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.